JAMA Dermatol

Guselkumab shows strong efficacy for scalp psoriasis across all skin tones

June 27, 2025

Guselkumab provides robust, durable efficacy and quality-of-life improvement for moderate to severe scalp psoriasis in patients across the skin-tone spectrum, supporting its use in populations historically underrepresented in clinical trials.

Study details: Cohort B of the VISIBLE Phase 3b randomized, double-blind, placebo-controlled trial (NCT05272150) evaluated guselkumab 100 mg in 108 participants with moderate to severe scalp psoriasis across all skin tones. Participants were randomized 3:1 to receive guselkumab or placebo at weeks 0 and 4, then q8wks. Co-primary endpoints were scalp-specific Investigator Global Assessment (ss-IGA) 0/1 and Psoriasis Scalp Severity Index (PSSI) 90 at week 16.

Results: At week 16, 68.4% of guselkumab-treated patients achieved ss-IGA 0/1 vs. 11.5% with placebo, and 65.8% achieved PSSI 90 vs. 3.8% with placebo (P < 0.001 for both). Complete scalp clearance (ss-IGA 0) was seen in 57.9% vs. 3.8%. Improvements in quality of life and scalp itch were significant and sustained through week 48. Infections were the most common adverse event.

Source:

McMichael A; VISIBLE Trial Investigators, et al. (2025, June 25). JAMA Dermatol. Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/40560554/